• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

酒精性肝硬化患者发生肝细胞癌的风险:一项丹麦全国队列研究。

Risk for hepatocellular carcinoma in patients with alcoholic cirrhosis: a Danish nationwide cohort study.

机构信息

Aarhus University Hospital, Nørrebrogade 44, Aarhus 8000 C, Denmark.

出版信息

Ann Intern Med. 2012 Jun 19;156(12):841-7, W295. doi: 10.7326/0003-4819-156-12-201206190-00004.

DOI:10.7326/0003-4819-156-12-201206190-00004
PMID:22711076
Abstract

BACKGROUND

Patients with alcoholic cirrhosis are at higher risk for hepatocellular carcinoma (HCC). The role of HCC surveillance for these patients is undefined.

OBJECTIVE

To provide population-based estimates of HCC incidence and comparisons of HCC-related mortality and total mortality among patients with alcoholic cirrhosis as a basis for assessing the role of HCC surveillance.

DESIGN

Nationwide, registry-based, historical cohort study.

SETTING

Denmark.

PATIENTS

All Danish citizens with a first-time hospital diagnosis of alcoholic cirrhosis from 1993 to 2005.

MEASUREMENTS

Hepatocellular carcinoma incidence and mortality starting 1 year after diagnosis of alcoholic cirrhosis through 2009; ratio of HCC-related mortality to total mortality.

RESULTS

Among 8482 patients, 169 developed HCC. A total of 5734 patients died, 151 of whom had developed HCC. Five-year cumulative HCC risk was 1.0% (95% CI, 0.8% to 1.3%), and 5-year cumulative mortality was 43.7% (CI, 42.6% to 44.7%). Only 1.8% of all deaths were HCC-related. In sensitivity analyses that included all possible HCC diagnoses and a subpopulation of patients who were followed by hepatologists, the highest 5-year HCC risk was 1.9% (CI, 0.8% to 3.9%). These patients did not have higher mortality than patients in the nationwide cohort.

LIMITATION

Cirrhosis and HCC diagnoses were made by hospital physicians without uniform clinical criteria, and use of registry data precluded detailed information on clinical care of patients, including HCC surveillance.

CONCLUSION

Danish patients with alcoholic cirrhosis have a low risk for HCC, and HCC contributes little to their high mortality. On the basis of these data, HCC surveillance would be expected to have a minimal effect on mortality and is unlikely to be cost-effective.

摘要

背景

患有酒精性肝硬化的患者发生肝细胞癌(HCC)的风险较高。对于这些患者,HCC 监测的作用尚未明确。

目的

提供 HCC 发病率的基于人群的估计值,并比较酒精性肝硬化患者的 HCC 相关死亡率和总死亡率,以此评估 HCC 监测的作用。

设计

全国范围内,基于登记的历史性队列研究。

地点

丹麦。

患者

1993 年至 2005 年期间首次在丹麦被诊断为酒精性肝硬化的所有丹麦公民。

测量指标

自酒精性肝硬化诊断后 1 年开始至 2009 年的 HCC 发病率和死亡率;HCC 相关死亡率与总死亡率之比。

结果

在 8482 例患者中,有 169 例发生 HCC。共有 5734 例患者死亡,其中 151 例发生 HCC。5 年 HCC 累积风险为 1.0%(95%CI,0.8%1.3%),5 年累积死亡率为 43.7%(CI,42.6%44.7%)。所有死亡中仅有 1.8%与 HCC 相关。在包括所有可能的 HCC 诊断的敏感性分析以及接受肝病专家随访的患者亚群中,5 年 HCC 最高风险为 1.9%(CI,0.8%~3.9%)。这些患者的死亡率并未高于全国性队列中的患者。

局限性

肝硬化和 HCC 的诊断是由医院医生做出的,没有统一的临床标准,并且使用登记数据限制了患者临床治疗的详细信息,包括 HCC 监测。

结论

丹麦患有酒精性肝硬化的患者 HCC 风险较低,HCC 对其高死亡率的贡献较小。根据这些数据,HCC 监测对死亡率的影响预计很小,并且不太可能具有成本效益。

相似文献

1
Risk for hepatocellular carcinoma in patients with alcoholic cirrhosis: a Danish nationwide cohort study.酒精性肝硬化患者发生肝细胞癌的风险:一项丹麦全国队列研究。
Ann Intern Med. 2012 Jun 19;156(12):841-7, W295. doi: 10.7326/0003-4819-156-12-201206190-00004.
2
Risk of hepatocellular carcinoma in Danish outpatients with alcohol-related cirrhosis.丹麦酒精性肝硬化门诊患者的肝细胞癌风险。
J Hepatol. 2020 Nov;73(5):1030-1036. doi: 10.1016/j.jhep.2020.05.043. Epub 2020 Jun 5.
3
Annual incidence of hepatocellular carcinoma among patients with alcoholic cirrhosis and identification of risk groups.酒精性肝硬化患者中肝细胞癌的年发病率和危险人群的确定。
Clin Gastroenterol Hepatol. 2013 Jan;11(1):95-101. doi: 10.1016/j.cgh.2012.09.007. Epub 2012 Sep 13.
4
Estimate of hepatocellular carcinoma incidence in patients with alcoholic cirrhosis.估算酒精性肝硬化患者肝细胞癌的发病率。
J Hepatol. 2018 Dec;69(6):1274-1283. doi: 10.1016/j.jhep.2018.07.022. Epub 2018 Aug 6.
5
Chemokine RANTES promoter dimorphisms and hepatocellular carcinoma occurrence in patients with alcoholic or hepatitis C virus-related cirrhosis.趋化因子 RANTES 启动子二态性与酒精性或丙型肝炎病毒相关肝硬化患者肝细胞癌的发生。
Cancer Epidemiol Biomarkers Prev. 2011 Jul;20(7):1439-46. doi: 10.1158/1055-9965.EPI-11-0341. Epub 2011 May 24.
6
The clinical course of alcoholic cirrhosis: development of comorbid diseases. A Danish nationwide cohort study.酒精性肝硬化的临床病程:合并症的发展。一项丹麦全国队列研究。
Liver Int. 2016 Nov;36(11):1696-1703. doi: 10.1111/liv.13151. Epub 2016 May 18.
7
Cirrhosis and mortality risks of biopsy-verified alcoholic pure steatosis and steatohepatitis: a nationwide registry-based study.基于全国登记数据库的研究:经活检证实的酒精性单纯性脂肪变性和脂肪性肝炎的肝硬化和死亡率风险。
Aliment Pharmacol Ther. 2012 Jun;35(11):1336-42. doi: 10.1111/j.1365-2036.2012.05091.x. Epub 2012 Apr 10.
8
PNPLA3 rs738409, hepatocellular carcinoma occurrence and risk model prediction in patients with cirrhosis.载脂蛋白 L3 基因 rs738409 多态性与肝硬化患者肝细胞癌发生及风险预测模型的建立
J Hepatol. 2013 Feb;58(2):312-8. doi: 10.1016/j.jhep.2012.09.036. Epub 2012 Oct 13.
9
Virological suppression does not prevent the development of hepatocellular carcinoma in HBeAg-negative chronic hepatitis B patients with cirrhosis receiving oral antiviral(s) starting with lamivudine monotherapy: results of the nationwide HEPNET. Greece cohort study.抗病毒治疗不能预防拉米夫定单药起始治疗的 HBeAg 阴性代偿期乙型肝炎肝硬化患者发生肝癌:全国性 HEPNET. 希腊队列研究结果。
Gut. 2011 Aug;60(8):1109-16. doi: 10.1136/gut.2010.221846. Epub 2011 Jan 26.
10
Analysis of risk factors for hepatocellular carcinoma in patients with HBs antigen- and anti-HCV antibody-negative alcoholic cirrhosis: clinical significance of prior hepatitis B virus infection.乙肝表面抗原和抗丙型肝炎病毒抗体阴性的酒精性肝硬化患者肝细胞癌危险因素分析:既往乙型肝炎病毒感染的临床意义
Alcohol Clin Exp Res. 2003 Aug;27(8 Suppl):47S-51S. doi: 10.1097/01.ALC.0000079449.47468.B0.

引用本文的文献

1
HEPPAR1 and PIWIL2 as Panel Markers for Hepatocellular Carcinoma.HEPPAR1 和 PIWIL2 作为肝细胞癌的标志物组合。
Asian Pac J Cancer Prev. 2024 Jun 1;25(6):2123-2131. doi: 10.31557/APJCP.2024.25.6.2123.
2
Hepatocellular Carcinoma: Prevention, Diagnosis, and Treatment.肝细胞癌:预防、诊断和治疗。
Med Princ Pract. 2024;33(5):414-423. doi: 10.1159/000539349. Epub 2024 May 21.
3
Regular Alpha-Fetoprotein Tests Boost Curative Treatment and Survival for Hepatocellular Carcinoma Patients in an Endemic Area.定期甲胎蛋白检测提高了某流行地区肝细胞癌患者的治愈性治疗效果及生存率。
Cancers (Basel). 2023 Dec 28;16(1):150. doi: 10.3390/cancers16010150.
4
Changing Epidemiology of Hepatocellular Carcinoma Within the United States and Worldwide.美国及全球肝细胞癌流行病学的变化
Surg Oncol Clin N Am. 2024 Jan;33(1):1-12. doi: 10.1016/j.soc.2023.06.004. Epub 2023 Aug 31.
5
Insights into Hepatocellular Carcinoma in Patients with Thalassemia: From Pathophysiology to Novel Therapies.铁过载相关肝细胞癌的病理生理学机制与新型治疗策略
Int J Mol Sci. 2023 Aug 10;24(16):12654. doi: 10.3390/ijms241612654.
6
Gender Differences in the Pathogenesis and Risk Factors of Hepatocellular Carcinoma.肝细胞癌发病机制及危险因素中的性别差异
Biology (Basel). 2023 Jul 11;12(7):984. doi: 10.3390/biology12070984.
7
Global prevalence, incidence, and outcomes of alcohol related liver diseases: a systematic review and meta-analysis.全球酒精相关性肝病的患病率、发病率和结局:系统评价和荟萃分析。
BMC Public Health. 2023 May 11;23(1):859. doi: 10.1186/s12889-023-15749-x.
8
Spontaneously Ruptured Hepatocellular Carcinoma: Computed Tomography-Based Assessment.自发性破裂肝细胞癌:基于计算机断层扫描的评估
Diagnostics (Basel). 2023 Mar 7;13(6):1021. doi: 10.3390/diagnostics13061021.
9
Global epidemiology of alcohol-associated cirrhosis and HCC: trends, projections and risk factors.全球酒精性肝硬化和 HCC 的流行病学:趋势、预测和危险因素。
Nat Rev Gastroenterol Hepatol. 2023 Jan;20(1):37-49. doi: 10.1038/s41575-022-00688-6. Epub 2022 Oct 18.
10
The Role of Sex in Acute and Chronic Liver Damage.性别在急性和慢性肝损伤中的作用。
Int J Mol Sci. 2022 Sep 13;23(18):10654. doi: 10.3390/ijms231810654.